雖然這篇Odiparcil鄉民發文沒有被收入到精華區:在Odiparcil這個話題中,我們另外找到其它相關的精選爆讚文章
[爆卦]Odiparcil是什麼?優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#1Odiparcil - Inventiva Pharma
Odiparcil, an orally-available small molecule that can potentially decrease the lysosomal accumulation of chondroitin sulfate (CS) and dermatan sulfate (DS) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#2Odiparcil, a potential glycosaminoglycans clearance ... - NCBI
由 E Entchev 著作 · 2020 · 被引用 7 次 — Odiparcil given orally was efficacious for treating Arsb - mice, a model mimicking MPS VI disease. Odiparcil treatment led to a reduction of GAG ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#3A Study in MPS VI to Assess Safety and Efficacy of Odiparcil
Odiparcil is an orally active compound that allows the synthesis of soluble glycosaminoglycans (GAGs), mainly chondroitin sulfate (CS) and dermatane sulfate ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#4Inventiva Pharma - Odiparcil - AdisInsight
Odiparcil is an analog of beta-d-xyloside, which acts as a substrate for galactosyl transferase I (GT1), a contributor to GAG synthesis. GTI then incorporates ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#5(PDF) Odiparcil, a potential glycosaminoglycans clearance ...
... Odiparcil, the β-1,4-galactosyltransferase (B4GalT7) decoy substrate, modifies GAG synthesis and facilitates the production of soluble GAG ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#6Odiparcil, a potential glycosaminoglycans clearance therapy ...
Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI—Evidence from in vitro and in vivo models.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#7ODIPARCIL - Inxight Drugs
Odiparcil is a novel, orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#8Odiparcil (SB-424323) | Thrombin Inhibitor | MedChemExpress
Odiparcil (SB-424323) is an orally active beta-d-thioxyloside analog with antithrombotic activity associated with a reduced risk of adverse bleeding events.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#9Odiparcil: Uses, Interactions, Mechanism of Action - DrugBank
This compound belongs to the class of organic compounds known as coumarins and derivatives. These are polycyclic aromatic compounds containing a ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#10A Study in MPS VI to Assess Safety and Efficacy of Odiparcil
Study to investigate the fate of odiparcil since its administration up to the point is completely eliminated, its safety and efficacy in patients 16 years ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#11Inventiva's latest research on odiparcil's mechanism of action ...
Odiparcil is an orally-available small molecule that acts on the underlying cause of the symptoms of mucopolysaccharidosis (MPS), a group of ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#12在MPS VI 中评估Odiparcil 的安全性和可用性的研究
粘多糖贮积症(MPS)是一种遗传的遗传,其特征是糖类还原酶的降解酶体贫乏(GAG)。因为MPS 的血管性差,治疗MPS 的医疗还可以重新进入血脑知识和眼并进入Odiparcil 是 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#13Odiparcil | Targetmol
Odiparcil is an orally active beta-d-thioxyloside analog. Odiparcil is an indirect thrombin inhibitor that exerts its anticoagulant effect through ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#14Search Orphan Drug Designations and Approvals
Generic Name: odiparcil. Date Designated: 08/03/2017. Orphan Designation: Treatment of mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#15MPS VI associated ocular phenotypes in an ... - Science Direct
Orally administered odiparcil markedly reduced GAG accumulation in the eyes of MPS VI Arsb − mice in both disease models and restored the ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#16Odiparcil, a potential glycosaminoglycans ... - HAL-Inserm
In vitro, in bovine aortic endothelial cells, odiparcil stimulated the ... was investigated in skin fibroblasts from MPS VI patients where odiparcil was ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#17Odiparcil,粘多糖贮积症VI中潜在的糖胺聚糖清除疗法 - X-MOL
Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#18odiparcil - Wikidata
Odiparcil. In more languages. Spanish. No label defined. compuesto químico. Traditional Chinese. No label defined. 化合物. Chinese. No label defined.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#19GSK 424323 | Odiparcil | SB424323;GSK424323 - Axon ...
Odiparcil | Anti-thrombotic | SB 424323 | GSK 424323 | Odiparcil | SB424323;GSK424323 | CAS [137215-12-4] | Axon 1536 | Axon Ligand™ with >99% purity ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#20Use of Odiparcil in the Treatment of a Mucopolysaccharidosis
US20150099789A1 - Use of Odiparcil in the Treatment of a Mucopolysaccharidosis - Google ... 229950005036 Odiparcil Drugs 0.000 title claims description 42 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#21Odiparcil | 137215-12-4 | Biosynth Carbosynth
Buy high quality Odiparcil 137215-12-4 from Biosynth Carbosynth. ... Odiparcil. Dipeptidyl peptidase 4 (DPP4) inhibitor.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#22Outcomes of the first phase IIa study with odiparcil - Wiley ...
Enzyme replacement therapy (ERT) of MPS VI has limited effects on ophthalmic, cardiovascular, and skeletal systems. Odiparcil is an orally ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#231903-public-summary-opinion-orphan-designation-odiparcil ...
EMA/476085/2017. Public summary of opinion on orphan designation. Odiparcil for the treatment of mucopolysaccharidosis type VI (Maroteaux-.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#24Odiparcil development advances with recruitment of first ...
Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS VI children and adults Study conducted in ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#25IMPROVES: A Phase IIa Study to Investigate Safety ... - Orphanet
The portal for rare diseases and orphan drugs · IMPROVES: A Phase IIa Study to Investigate Safety, Pharmacokinetics, and Efficacy of Odiparcil in Patients 16 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#26A Study in MPS VI to Assess Safety and Efficacy of Odiparcil
The neosynthesized solubles GAGs are then excreted in urine. By diverting endogenous GAG synthesis to the synthesis of soluble odiparcil linked GAGs, odiparcil ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#27Inventiva's odiparcil nabs accelerated review in U.S. for a rare ...
The FDA has designated Fast Track status to Inventiva's (NASDAQ:IVA) odiparcil for the treatment of MPS type VI (MPS VI), a rare and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#28Odiparcil | C15H16O6S | ChemSpider
Odiparcil. Molecular FormulaC15H16O6S; Average mass324.349 Da; Monoisotopic mass324.066772 Da; ChemSpider ID187565. defined stereocentres ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#29Odiparcil | Thrombin | 陶术生物
Odiparcil is an orally active beta-d-thioxyloside analog. Odiparcil is an indirect thrombin inhibitor that exerts its anticoagulant effect through ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#30ODIPARCIL
物质名称, ODIPARCIL. 异名/同义词, 4-METHYL-7-(5-THIO-.BETA.-D-XYLOPYRANOSYLOXY)-2H-CHROMEN-2-ONE ODIPARCIL ODIPARCIL [INN] ODIPARCIL [WHO-DD].
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#31Inventiva Announces New Compelling Data On ... - BioSpace
Inventiva Announces New Compelling Data On Odiparcil / IVA336 To Be Presented At MPS Society National Conference - read this article along ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#32CAS 137215-12-4 odiparcil - BOC Sciences
Odiparcil is a novel thrombin inhibitor as a beta-d-thioxyloside analog originated by Fournier Pharma. It is also a Glycosaminoglycan stimulant.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#33BRIEF-Odiparcil awarded Orphan Drug Designation by the FDA
ODIPARCIL AWARDED ORPHAN DRUG DESIGNATION FOR TREATMENT OF MPS VI BY FDA. * MPS VI (MAROTEAUX-LAMY SYNDROME), IS A RARE PEDIATRIC GENETIC ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#34Odiparcil Clinical Trials 2022 | Clincosm
odiparcil. Odiparcil is a drug used to treat Fibrillation, Atrial, Atrial Fibrillation, Deep Vein Thrombosis, and other conditions. Odiparcil is not being ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#35Odiparcil, a potential glycosaminoglycans clearance therapy ...
In vitro, in bovine aortic endothelial cells, odiparcil stimulated the secretion ... Furthermore, odiparcil diminished the pathological cartilage thickening ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#36Odiparcil - Chemical Details
Odiparcil. 137215-12-4 | DTXSID4057639. Searched by DTXSID4057639. Details; Executive Summary; Properties; Env. Fate/Transport; Hazard; Safety > GHS Data ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#37use of odiparcil in the treatment of a mucopolysaccharidosis
1. WO2015049471 - USE OF ODIPARCIL IN THE TREATMENT OF A MUCOPOLYSACCHARIDOSIS ... The present invention relates to the use of 4-methyl-2-oxo-2H-1-benzopyran-7-yl ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#38INVENTIVA obtient le statut « Fast Track » de la FDA pour l ...
(AOF) - Inventiva a annoncé que la Food and Drug Administration (FDA) américaine a accordé le statut « Fast Track » à odiparcil, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#39Inventiva announces positive results from Phase IIa clinical ...
o Safety primary objective of the study met o Positive results observed regarding the efficacy of odiparcil, especially in hard- to-reach ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#40Mucopolysaccharidosis Type VI, an Updated Overview of the ...
Odiparcil has proven to reduce intracellular CS in human MPS VI fibroblasts, and to ameliorate tissue GAG accumulation, corneal morphology and opacification and ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#41MPS VI biomarker Feb. 2018
with a new treatment such as odiparcil. The study enrolled 12 subjects: six MPS VI patients, who have been treated with galsulfase for 10 ± 3.1 years.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#42INVENTIVA: Odiparcil development advances with recruitment ...
Investegate announcements from INVENTIVA, Odiparcil development advances with recruitment of first patients in a new biomarker study in MPS ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#43ICTRP Search Portal
A phase IIa study to investigate safety, pharmacokinetics, and efficacy of odiparcil in patients 16 years and above with mucopolysaccharidosis ( ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#44Odiparcil 3D-BO167288 | CymitQuimica
Odiparcil. CAS: 137215-12-4. Ref. 3D-BO167288. Estimated delivery in United States, on Tuesday 8 Feb 2022. Enzyme Modulators · Organometallic Ligands.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#45Odiparcil
Odiparcil has been in phase II clinical trials for the treatment of deep venous thrombosis (DVT), thrombotic cardiovascular events (TCE) and hypertension.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#46Synopsis - EU Clinical Trials Register
The primary objective of the trial was to assess the safety and efficacy of odiparcil in the prevention of venous thromboembolism (VTE) following total knee ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#47Inventiva's latest research on odiparcil's ... - TeleTrader.com
In a mouse genetic model of MPS VI, treatment with odiparcil was ... clinical trial with odiparcil in MPS VI at the end of last year.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#48Odiparcil | CAS#:137215-12-4 | Chemsrc
Chemsrc provides Odiparcil(CAS#:137215-12-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#49Stimulation by odiparcil of GAG secretion in BAE cells. - Public ...
Stimulation by odiparcil of GAG secretion in BAE cells. · Eugeni Entchev · Ingrid Jantzen · Philippe Masson · Stephanie Bocart · Bruno Bournique ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#50Inventiva's Odiparcil awarded ODD by EMA to treat MPS VI
Odiparcil (formerly IVA336), an orally available therapy, is being developed as a potential therapy for MPS I, II, and VI patients. Professor ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#51137215-12-4 | Odiparcil - SB 424323 | C₁₅H₁₆O₆S | TRC
Category, Standards; Pharmaceutical/API Drug Impurities/Metabolites;. Applications, Odiparcil - SB 424323 (cas# 137215-12-4) is a useful research chemical.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#52Comme prévu, le statut de médicament orphelin pour l'Odiparcil
Inventiva vient de recevoir de la FDA, l'autorité sanitaire américaine, le statut de médicament orphelin pour l'Odiparcil, son candidat ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#53Odiparcil is a promising substrate reduction therapy in MPS VI ...
Do you detect an error, an omission? Contribute! Title. Odiparcil is a promising substrate reduction ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#54odiparcil | 137215-12-4
Visit ChemicalBook To find more odiparcil(137215-12-4) information like chemical properties,Structure,melting point,boiling point,density,molecular formula ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#55Odiparcil - acadpharm
L'odiparcil agit en facilitant la formation de glycosaminoglycanes solubles qui peuvent alors être excrétées dans l'urine plutôt que s'accumuler dans les ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#5608/29/17 – Inventiva's Odiparcil Receives Orphan Drug ...
08/29/17 – Inventiva's Odiparcil Receives Orphan Drug Designation in MPS VI ; Download, 6 ; Stock, ∞ ; Total Files, 1 ; Size, 293.13 KB ; Create Date, September 8, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#57Inventiva aims for $90M Nasdaq IPO after positive phase 2
The offering will also bankroll odiparcil, which Inventiva is developing for mucopolysaccharidosis type VI, a rare genetic disorder. (Natalie Murphy).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#58Odiparcil is a promising substrate reduction ... - ScienceON
Odiparcil is a promising substrate reduction therapy in MPS VI murine model 인용. Molecular genetics and metabolism v.123 no.2 , 2018년, pp.S42 - S43.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#59FDA授予Inventiva治疗MPS VI药物孤儿药称号 - 新浪医药新闻
15日,专注于开发治疗纤维化药物的公司Inventiva宣布,FDA授予治疗MPS VI药物odiparcil孤儿药的称号。
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#60MPS VI (maladie de Maroteau-Lamy) : le laboratoire ...
MPS VI (maladie de Maroteau-Lamy) : le laboratoire INVENTIVA lance son essai clinique Safe-KIDD, avec sa molécule Odiparcil.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#6186-6321-92 Odiparcil 1mg CAS No.137215-12-4 A21584-1
アズワンの【AXEL】86-6321-92 Odiparcil 1mg CAS No.137215-12-4 A21584-1のコーナーです。AXELは研究開発、医療介護、生産現場、食品衛生など幅広い分野に550万点 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#62Buy Odiparcil - SB 424323, 5mg O882553-5mg in India | Biomall
Buy online Odiparcil - SB 424323, 5mg O882553-5mg 137215-12-4 at best price in India on Biomall. Request quote for laboratory supplies, chemicals & life ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#63la FDA accorde la désignation de « maladie pédiatrique rare
Nous sommes heureux de poursuivre notre collaboration avec la FDA afin de faire progresser odiparcil comme traitement dans cette maladie rare et ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#64(12) Patent Application Publication (10) Pub. No.: US 2015 ...
The present invention relates to the use of Odiparcil, or of a pharmaceutical composition containing this com.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#65Quietly Disappearing From the Skies | Science | AAAS
Among them were a beta-3 agonist for diabetes (solabegron) and a glycoside-based thrombin inhibitor (odiparcil).
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#66Glaxo Pipeline Dented as Mid-Stage Drugs Dropped - CNBC
Notable losses among drugs that have been terminated include odiparcil for thrombosis, solabegron for diabetes and four separate cancer ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#67Inventiva Announces New Compelling Data ... - Business Wire
Odiparcil could prove beneficial to MPS patients as a substrate reduction therapy as a stand-alone treatment or in adjunction to current ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#68Odiparcil, a potential glycosaminoglycans clearance ... - ebsco
The therapeutic efficacy of odiparcil was similar in models of early (treatment starting in juvenile, 4 weeks old mice) or established disease ( ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#69Inventiva announces positive results ... - PipelineReview.com
Safety primary objective of the study met; Positive results observed regarding the efficacy of odiparcil, especially in
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#70Study: Odiparcil Shows Positive Results in Treatment of ...
Inventiva has recently completed Phase IIa of their clinical trial of odiparcil, a drug made for the treatment of mucopolysaccharidosis type ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#71A Phase IIa Study to Investigate Safety, Pharmacokinetics, and ...
Odiparcil is an orally active compound that allows the synthesis of soluble glycosaminoglycans (GAGs), mainly chondroitin sulfate (CS) and dermatane sulfate (DS) ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#72Inventiva : La FDA désigne odiparcil médicament orphelin
Odiparcil est un médicament par voie orale développé pour le traitement des MPS I, II, et VI. Inventiva lance actuellement une étude ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#73Inventiva odiparcil gets FDA fast track designation for ...
Inventiva's (PSE:IVA; NASDAQ:IVA) odiparcil received FDA fast track designation for the treatment of mucopolysaccharidosis (MPS) Type VI, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#74Chemical Substance Search - eChemPortal
Odiparcil, 137215-12-4. (CAS Number) ... ACToR. Odiparcil, 137215-12-4. (CAS Number) ... Chemicals Dashboard. Hits: 1 - 2/2. Page 1 of 1. Rows per page:.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#75Inventiva Announces End of Patient Recruitment for its Phase ...
Last patient enrolled in the Phase IIa iMProveS trial evaluating odiparcil in MPS VI patients. 20 patients included in the study, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#76Inventiva Receives A €3.5M Milestone Payment From AbbVie
The Company is currently investigating odiparcil in a Phase IIa clinical trial for the treatment of patients with the MPS VI subtype. In ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#77Odiparcil CAS No. : 137215-12-4 - ChemScene
ChemScene Provide Odiparcil(CAS 137215-12-4)In-stock or Backordered impurities,Bulk custom synthesis,Formular C15H16O6S,MW 324.35 bulk manufacturing, ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#78Mucopolysaccharidoses I and II: Brief Review of Therapeutic ...
Currently, Inventiva Pharma is developing an orally administrable small molecule called Odiparcil for the treatment of several types of MPS.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#79Inventiva odiparcil 12 Jul 2018 | ORD India
ORD India > Clinical Trials Update > Phase IIb trial in adult MPS VI ( Mucopolysacridosis ) > Inventiva odiparcil 12 Jul 2018 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#80tepzz 857z ¥b_t - ep 2 857 023 b1 - European Patent Office
[0001] La présente invention concerne l'utilisation de l'odiparcil, ou d'une composition pharmaceutique contenant ce.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#81Inventiva: avis favorable pour une désignation d'odiparcil.
Inventiva annonce que l'Agence européenne du médicament (EMA) a rendu un avis favorable pour la désignation d'odiparcil (anciennement ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#82Inventiva présentera des données in vivo sur odiparcil lors du ...
Inventiva estime qu'odiparcil pourrait significativement améliorer la vie des patients atteints de MPS VI et devenir le nouveau traitement de ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#83Inventiva SA - SEC.gov
Odiparcil has received orphan drug designation from the FDA and EMA and rare pediatric disease designation from the FDA for the treatment of MPS VI. Our ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#84Odiparcil pour traiter la MPS VI - Doctissimo
Après les USA, l'Europe désigne Odiparcil comme médicament orphelin contre la MPS VI · MPS VI, une maladie rare dégénérative · Une étude clinique ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#85Odiparcil | Chemical Substance Information | J-GLOBAL
4-Methyl-7-[(5-thio-β-D-xylopyranosyl)oxy]-2H-1-benzopyran-2-one; Odiparcil; オジパルシル. CAS registry number: 137215 ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#86New Therapeutic Agents in Thrombosis and Thrombolysis
Three such drugs have been developed: odiparcil is an indirect inhibitor, whereas ximelagatran and dabigatran etexilate are direct thrombin inhibitors ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#87Advances in Carbohydrate Chemistry and Biochemistry
In contrast, rather than inhibiting biosynthesis, the orally available 5-thio-β- D -xyloside odiparcil, (41)177 reduces cellular GAG levels by competing ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#88Inventiva publie sa position de trésorerie et son chiffre d ...
En 2019, Inventiva a publié des résultats positifs de son étude clinique de Phase IIa évaluant odiparcil pour le traitement des patients adultes ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#89Inventiva : La position de trésorerie s'élevait à 95,4 ME au 31 ...
Point d'étape sur la stratégie de développement d'odiparcil - prévu pour 2022. Prochaines participations à des conférences investisseurs.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#90Carbohydrates in Sustainable Development I
Within this series, Odiparcil® was evaluated in clinical trials in patients for the prevention of venous thromboembolism [74]. Recently, synthesis of new ...
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#91Stereoselective Synthesis of Drugs and Natural Products
... by the xyloside induction of circulating glycosaminoglycans (GAGs).131 Odiparcil is an example, marketed by GlaxoSmithKline (London, U.K.).132 28.4.3.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?> -
//=++$i?>//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['title'])?>
#92Venous Thromboembolic Disease - 第 75 頁 - Google 圖書結果
There was an oral indirect thrombin inhibitor in development, odiparcil.10 However, its development was stopped at phase II.
//="/exit/".urlencode($keyword)."/".base64url_encode($si['_source']['url'])."/".$_pttarticleid?>//=htmlentities($si['_source']['domain'])?>
odiparcil 在 コバにゃんチャンネル Youtube 的精選貼文
odiparcil 在 大象中醫 Youtube 的最佳貼文
odiparcil 在 大象中醫 Youtube 的精選貼文